Law in the Internet Society

View   r2  >  r1  ...
BahradSokhansanjFirstPaper 2 - 27 Oct 2011 - Main.BahradSokhansanj
Line: 1 to 1
 
META TOPICPARENT name="FirstPaper"
It is strongly recommended that you include your outline in the body of your essay by using the outline as section titles. The headings below are there to remind you how section and subsection titles are formatted.

Who Will Own The Future of Medicine?

Added:
>
>		Consider this article from 1991. Nature 1991 Paradigm Shift in Biology
 Drugs are just information products
Changed:
<
<		Rebecca Eisenberg has written about the observations that drugs are information products whose only value is information about efficacy and safety in FDA clinical studies (so she extends that to say that this is the avenue for ensuring exclusivity).
>
>		 Eisenberg article has written about the observations that drugs are information products whose only value is information about efficacy and safety in FDA clinical studies (so she extends that to say that this is the avenue for ensuring exclusivity).
 Next-generation medical intervention will be information products in more ways, because they will be tied to personal genetic information.
Line: 35 to 37
 Then we have something with genomics research by people sequencing their own genomes -- the most prominent effort in this regard is 23andWe, which has already published some results of genome-wide studies that appear to check out, including work on Parkinson's

-- BahradSokhansanj - 25 Oct 2011

Added:
>
>

META FILEATTACHMENT attachment="Nature_1991_Paradigm_shift_in_Biology.pdf" attr="h" comment="" date="1319718531" name="Nature_1991_Paradigm_shift_in_Biology.pdf" path="Nature_1991_Paradigm_shift_in_Biology.pdf" size="142040" stream="Nature_1991_Paradigm_shift_in_Biology.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="72FordhamLRev477_pharma_product_innovation_patents_Eisenberg_2003.pdf" attr="h" comment="" date="1319718937" name="72FordhamLRev477_pharma_product_innovation_patents_Eisenberg_2003.pdf" path="72FordhamLRev477 pharma product innovation patents Eisenberg 2003.pdf" size="992453" stream="72FordhamLRev477 pharma product innovation patents Eisenberg 2003.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="PLOSGenet_web-based_gwas_identifies_parkinsons_genes_2011.pdf" attr="h" comment="" date="1319719162" name="PLOSGenet_web-based_gwas_identifies_parkinsons_genes_2011.pdf" path="PLOSGenet web-based gwas identifies parkinsons genes 2011.pdf" size="451716" stream="PLOSGenet web-based gwas identifies parkinsons genes 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="14DrugDiscToday261_collaborative_drug_discovery_tools_2009.pdf" attr="h" comment="" date="1319719194" name="14DrugDiscToday261_collaborative_drug_discovery_tools_2009.pdf" path="14DrugDiscToday261 collaborative drug discovery tools 2009.pdf" size="3469500" stream="14DrugDiscToday261 collaborative drug discovery tools 2009.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="19HealthEcon1002_drug_dev_costs_with_financial_risk_2010.pdf" attr="h" comment="" date="1319719247" name="19HealthEcon1002_drug_dev_costs_with_financial_risk_2010.pdf" path="19HealthEcon1002 drug dev costs with financial risk 2010.pdf" size="70694" stream="19HealthEcon1002 drug dev costs with financial risk 2010.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="25HealthAff420_Estimating_cost_new_drug_development_2006.pdf" attr="h" comment="" date="1319719269" name="25HealthAff420_Estimating_cost_new_drug_development_2006.pdf" path="25HealthAff420 Estimating cost new drug development 2006.pdf" size="146865" stream="25HealthAff420 Estimating cost new drug development 2006.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="22JHealthEcon151_drug_development_costs_2003.pdf" attr="h" comment="" date="1319719296" name="22JHealthEcon151_drug_development_costs_2003.pdf" path="22JHealthEcon151 drug development costs 2003.pdf" size="289492" stream="22JHealthEcon151 drug development costs 2003.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="28ManageDecisEcon469_cost_of_biopharma_rd_2007.pdf" attr="h" comment="" date="1319719323" name="28ManageDecisEcon469_cost_of_biopharma_rd_2007.pdf" path="28ManageDecisEcon469 cost of biopharma r&d 2007.pdf" size="163599" stream="28ManageDecisEcon469 cost of biopharma r&d 2007.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="Public_Citizen_Press_Room_Real_cost_of_drugs.pdf" attr="h" comment="" date="1319721578" name="Public_Citizen_Press_Room_Real_cost_of_drugs.pdf" path="Public Citizen Press Room Real cost of drugs.pdf" size="152289" stream="Public Citizen Press Room Real cost of drugs.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="Cochrane_statin_review_uncertainty_2011.pdf" attr="h" comment="" date="1319719379" name="Cochrane_statin_review_uncertainty_2011.pdf" path="Cochrane statin review uncertainty 2011.pdf" size="333145" stream="Cochrane statin review uncertainty 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="46AdvDrugDisc3_Lipinski_rule_of_five_2001.pdf" attr="h" comment="" date="1319719405" name="46AdvDrugDisc3_Lipinski_rule_of_five_2001.pdf" path="46AdvDrugDisc3 Lipinski rule of five 2001.pdf" size="160651" stream="46AdvDrugDisc3 Lipinski rule of five 2001.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="87ClinPharmTher534_open_source_drug_disc_Munos_2010.pdf" attr="h" comment="" date="1319719693" name="87ClinPharmTher534_open_source_drug_disc_Munos_2010.pdf" path="87ClinPharmTher534 open source drug disc Munos 2010.pdf" size="146127" stream="87ClinPharmTher534 open source drug disc Munos 2010.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="91Tubercul479_open_source_drug_discovery_for_TB_2011.pdf" attr="h" comment="" date="1319720111" name="91Tubercul479_open_source_drug_discovery_for_TB_2011.pdf" path="91Tubercul479 open source drug discovery for TB 2011.pdf" size="837783" stream="91Tubercul479 open source drug discovery for TB 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="100HealthPoly4_cost_of_drug_development_2010.pdf" attr="h" comment="" date="1319720143" name="100HealthPoly4_cost_of_drug_development_2010.pdf" path="100HealthPoly4 cost of drug development 2010.pdf" size="222929" stream="100HealthPoly4 cost of drug development 2010.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="467Nature650_life_hackers_2010.pdf" attr="h" comment="" date="1319720227" name="467Nature650_life_hackers_2010.pdf" path="467Nature650 life hackers 2010.pdf" size="392735" stream="467Nature650 life hackers 2010.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="Parke-Davis_v_HK_Mulford_189_F._95.pdf" attr="h" comment="" date="1319720484" name="Parke-Davis_v_HK_Mulford_189_F._95.pdf" path="Parke-Davis_v_HK_Mulford_189_F._95.pdf" size="1301851" stream="Parke-Davis_v_HK_Mulford_189_F._95.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="Assn_for_Molecular_Pathology_v_US_Patent_and_Trademark_Office.doc" attr="h" comment="" date="1319720799" name="Assn_for_Molecular_Pathology_v_US_Patent_and_Trademark_Office.doc" path="Ass'n for Molecular Pathology v US Patent and Trademark Office.doc" size="806691" stream="Ass'n for Molecular Pathology v US Patent and Trademark Office.doc" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="EurJNeuro_Reassessing_received_wisdom_in_ALS_by_PatientsLIkeMe_2011.pdf" attr="h" comment="" date="1319720849" name="EurJNeuro_Reassessing_received_wisdom_in_ALS_by_PatientsLIkeMe_2011.pdf" path="EurJNeuro Reassessing received wisdom in ALS by PatientsLIkeMe? 2011.pdf" size="58991" stream="EurJNeuro Reassessing received wisdom in ALS by PatientsLIkeMe? 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="PLOSGenet_web-based_participant-driven_studies_yield_novel_associations_2010.pdf" attr="h" comment="" date="1319720875" name="PLOSGenet_web-based_participant-driven_studies_yield_novel_associations_2010.pdf" path="PLOSGenet web-based participant-driven studies yield novel associations 2010.pdf" size="2302475" stream="PLOSGenet web-based participant-driven studies yield novel associations 2010.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="FDA_to_allow_cheaper_preterm_baby_drug_-_Wapo_033011.pdf" attr="h" comment="" date="1319720897" name="FDA_to_allow_cheaper_preterm_baby_drug_-_Wapo_033011.pdf" path="FDA to allow cheaper preterm baby drug - Wapo 033011.pdf" size="205486" stream="FDA to allow cheaper preterm baby drug - Wapo 033011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="NatBiotech_Clinical_discovery_through_PatientsLikeMe_2011.pdf" attr="h" comment="" date="1319720934" name="NatBiotech_Clinical_discovery_through_PatientsLikeMe_2011.pdf" path="NatBiotech Clinical discovery through PatientsLikeMe? 2011.pdf" size="511203" stream="NatBiotech Clinical discovery through PatientsLikeMe? 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="PLOSOne_personal_genomics_self-reported_trials_replication_2011.pdf" attr="h" comment="" date="1319721489" name="PLOSOne_personal_genomics_self-reported_trials_replication_2011.pdf" path="PLOSOne personal genomics self-reported trials replication 2011.pdf" size="1956951" stream="PLOSOne personal genomics self-reported trials replication 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="PLOSNTD_Kernel_for_Open_Source_Drug_Discovery_2009.pdf" attr="h" comment="" date="1319721532" name="PLOSNTD_Kernel_for_Open_Source_Drug_Discovery_2009.pdf" path="PLOSNTD Kernel for Open Source Drug Discovery 2009.pdf" size="1367225" stream="PLOSNTD Kernel for Open Source Drug Discovery 2009.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="Wired_UK_DIY_Genomics_Mar_11_2011.pdf" attr="h" comment="" date="1319721555" name="Wired_UK_DIY_Genomics_Mar_11_2011.pdf" path="Wired UK DIY Genomics Mar 11 2011.pdf" size="1053797" stream="Wired UK DIY Genomics Mar 11 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="12NatRevGen730_GWAS_privacy_risk_management_2011.pdf" attr="h" comment="" date="1319723137" name="12NatRevGen730_GWAS_privacy_risk_management_2011.pdf" path="12NatRevGen730 GWAS privacy risk management 2011.pdf" size="464324" stream="12NatRevGen730 GWAS privacy risk management 2011.pdf" user="Main.BahradSokhansanj" version="1"
META FILEATTACHMENT attachment="10CurrGenom493_metagenomics_review_2009.pdf" attr="h" comment="" date="1319723217" name="10CurrGenom493_metagenomics_review_2009.pdf" path="10CurrGenom493 metagenomics review 2009.pdf" size="358845" stream="10CurrGenom493 metagenomics review 2009.pdf" user="Main.BahradSokhansanj" version="1"

BahradSokhansanjFirstPaper 1 - 25 Oct 2011 - Main.BahradSokhansanj
Line: 1 to 1
Added:
>
>
META TOPICPARENT name="FirstPaper"
It is strongly recommended that you include your outline in the body of your essay by using the outline as section titles. The headings below are there to remind you how section and subsection titles are formatted.

Who Will Own The Future of Medicine?

Drugs are just information products Rebecca Eisenberg has written about the observations that drugs are information products whose only value is information about efficacy and safety in FDA clinical studies (so she extends that to say that this is the avenue for ensuring exclusivity).

Next-generation medical intervention will be information products in more ways, because they will be tied to personal genetic information.

I don't really care about treatment of acute conditions -- while there will be some personalization, things like treatment of infectious diseases will still likely be a mass approach, though there may be more refined diagnostic procedures, which are significant (who will control them? this can just be collected at the hospital level). Indeed, drug companies don't care about them. All the money is in chronic diseases, and/or making acute into chronic, or "preventive" treatment, which is basically just chronic but pre-symptomatic.

Prescription drug spending is a lot of money, but not all, and indeed what I'm talking about in terms of the future of medicine is a lot broader than drugs, because it also includes diagnostics and other kinds of physician "interventions" (and things like less ICU time) here is Kaiser's projected costs: Drug spending that is in 2009 approximately $250B more than doubling by 2020, driven by faster growth after a period of slower growth due to drugs coming off patents but with drugs having more exclusivity

Innovations happening now that are "open source" that I guess I have to talk about:

OpenNotebookScience, spearheaded by Jean-Claude Bradley at Drexel.

web-based platforms for collaborative drug discovery, like this product

the Open Source Drug Discovery project, which is working on TB (notably infectious disease)

drug costs have been estimated to be $802 million, though this is variable and is also subject to a lot of assumptions and it includes opportunity cost of capital, which is actually the majority of that figure ($574M). The people who came up with $802 came up with a similar $600-1B range for biotech products

What is a drug? Well, traditionally you go with the "Lipinski Rule of 5," based on certain physical properties, such as size and key chemical properties that make it compatible with metabolism. Of course, not every drug satisfies this rule (e.g. lithium carbonate)... also, it's sort of weird that biologics are treated differently than small molecule drugs when they are basically the same thing (though of course they are developed differently with different IP ramifications)

Also, biohacking and "garage biology" or DIY biology: OpenWetWare (closed access Nature article) or the Wired article I can also have a link to DIYBio, even New York City has Genspace

Also protein folding at home using passive grid computing. Aaron Chan's essay talks about some chintzy protein folding game stuff that isn't really all that interesting but has a "cool factor" that appeals to computer type people.

Community sourcing / social networking for patient experiences: PatientsLikeMe which has had some preliminary success in ALS being faster than traditional studies with similar results

Then we have something with genomics research by people sequencing their own genomes -- the most prominent effort in this regard is 23andWe, which has already published some results of genome-wide studies that appear to check out, including work on Parkinson's

-- BahradSokhansanj - 25 Oct 2011


Revision 2r2 - 27 Oct 2011 - 13:46:58 - BahradSokhansanj
Revision 1r1 - 25 Oct 2011 - 01:59:37 - BahradSokhansanj
This site is powered by the TWiki collaboration platform.
All material on this collaboration platform is the property of the contributing authors.
All material marked as authored by Eben Moglen is available under the license terms CC-BY-SA version 4.
Syndicate this site RSSATOM